FibroGen Inc. (NASDAQ:FGEN) went up by 8.86% from its latest closing price compared to the recent 1-year high of $30.12. The company’s stock price has collected 21.32% of gains in the last five trading sessions. Barron’s reported on 08/11/21 that The FDA Rejects FibroGen Drug. The Damage to the Stock Is Already Done.
Is It Worth Investing in FibroGen Inc. (NASDAQ :FGEN) Right Now?
Plus, the 36-month beta value for FGEN is at 0.90. Opinions of the stock are interesting as 0 analysts out of 7 who provided ratings for FibroGen Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 6 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $13.20, which is $2.39 above the current price. FGEN currently public float of 85.80M and currently shorts hold a 6.80% ratio of that float. Today, the average trading volume of FGEN was 951.26K shares.
FGEN’s Market Performance
FGEN stocks went up by 21.32% for the week, with a monthly jump of 26.14% and a quarterly performance of -16.20%, while its annual performance rate touched -59.90%. The volatility ratio for the week stands at 8.48% while the volatility levels for the past 30 days are set at 7.38% for FibroGen Inc. The simple moving average for the period of the last 20 days is 14.59% for FGEN stocks with a simple moving average of -11.10% for the last 200 days.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with Goldman repeating the rating for FGEN by listing it as a “Sell.” The predicted price for FGEN in the upcoming period, according to Goldman is $11 based on the research report published on September 22nd of the previous year 2021.
Stifel gave a rating of “Hold” to FGEN, setting the target price at $29 in the report published on July 16th of the previous year.
FGEN Trading at 9.65% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.12% of loss for the given period.
Volatility was left at 7.38%, however, over the last 30 days, the volatility rate increased by 8.48%, as shares surge +25.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.07% lower at present.
During the last 5 trading sessions, FGEN rose by +21.32%, which changed the moving average for the period of 200-days by -13.52% in comparison to the 20-day moving average, which settled at $9.54. In addition, FibroGen Inc. saw -23.33% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at FGEN starting from KEARNS THOMAS F JR, who sale 13,100 shares at the price of $11.58 back on Sep 15. After this action, KEARNS THOMAS F JR now owns 39,764 shares of FibroGen Inc., valued at $151,707 using the latest closing price.
Wettig Thane, the Chief Commercial Officer of FibroGen Inc., purchase 3,100 shares at $11.53 during a trade that took place back on Aug 26, which means that Wettig Thane is holding 48,816 shares at $35,743 based on the most recent closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- -122.62 for the present operating margin
- +88.24 for the gross margin
The net margin for FibroGen Inc. stands at -123.25. Equity return is now at value -118.10, with -35.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.10.